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Abstract
Motivation: Loss-of-function genetic variants are frequently associated with severe clinical pheno-
types, yet many are present in the genomes of healthy individuals. The available methods to as-
sess the impact of these variants rely primarily upon evolutionary conservation with little to no
consideration of the structural and functional implications for the protein. They further do not pro-
vide information to the user regarding specific molecular alterations potentially causative of
disease.
Results: To address this, we investigate protein features underlying loss-of-function genetic vari-
ation and develop a machine learning method, MutPred-LOF, for the discrimination of pathogenic
and tolerated variants that can also generate hypotheses on specific molecular events disrupted by
the variant. We investigate a large set of human variants derived from the Human Gene Mutation
Database, ClinVar and the Exome Aggregation Consortium. Our prediction method shows an area
under the Receiver Operating Characteristic curve of 0.85 for all loss-of-function variants and 0.75
for proteins in which both pathogenic and neutral variants have been observed. We applied
MutPred-LOF to a set of 1142 de novo vari3ants from neurodevelopmental disorders and find en-
richment of pathogenic variants in affected individuals. Overall, our results highlight the potential
of computational tools to elucidate causal mechanisms underlying loss of protein function in loss-
of-function variants.
Availability and Implementation: http://mutpred.mutdb.org
Contact: predrag@indiana.edu
1 Introduction
Genetic data-driven approaches to human health have resulted in
the implication of loss-of-function (LOF) variants in phenotypes
ranging from complex neuropsychiatric diseases to Mendelian blood
groups (Stenson et al., 2014). Loss-of-function variants include
frameshifting and stop variants and are of particular interest because
of their potentially profound impact on the mRNA transcript and
translated protein. Frameshifting variants are insertions and dele-
tions of nucleotides (indels) not divisible by three, causing a change
in the mRNA coding frame. Stop variants, on the other hand, entail
the gain or loss of stop codons in mRNA; stop-gain or nonsense
variants introduce a premature termination codon that truncates the
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protein, whereas stop-loss or nonstop variants alter the termination
codon and lead to elongated proteins.
Altered transcripts resulting from LOF variants are either
degraded at the mRNA or protein levels or rendered non-functional,
often leading to disease phenotypes. For example, disease-causing
stop variants are significantly enriched for alterations which activate
nonsense mediated decay, resulting in haploinsufficiency (Mort
et al., 2008). However, LOF variants can also be functionally and
phenotypically neutral; in fact, each human genome may contain
hundreds of frameshifting indels and dozens of stop variants with
little or no observable impact upon phenotype (Kircher et al., 2014;
MacArthur and Tyler-Smith, 2010; MacArthur et al., 2012; Sulem
et al., 2015; Thousand Genomes Project Consortium, 2010).
Robustness in the genome through gene duplication (Hsiao and
Vitkup, 2008) and compensatory mechanisms (Hu and Ng, 2012)
can result in the toleration of many LOF variants. Furthermore,
gene loss in regions under relaxed selection, including olfactory and
taste receptor genes, is typically tolerated (Risso et al., 2014).
Recently, there has been a growing interest in the phenotypic
and clinical roles of de novo LOF variants. For example, an esti-
mated one out of every hundred de novo LOF mutations contributes
to autism spectrum disorders (Ronemus et al., 2014). Data from the
Exome Aggregation Consortium (ExAC) found that the exomes of
60 706 individuals contain nearly sixty thousand non-singleton non-
sense variants while 3230 genes exhibit near-complete depletion
(Lek et al., 2016); therefore, a major challenge remains in under-
standing the nature and quantifying the impact of LOF variants in a
given genome. The lack of annotation for previously unseen genetic
variants in many such cases further highlights the need for sophisti-
cated prediction models specifically designed for LOF variants.
Unlike single nucleotide variants (Cline and Karchin, 2011), LOF
variants are not as well-studied. Early approaches used in the work of
Zia and Moses (2011), SIFT Indel (Hu and Ng, 2012) and NutVar
(Rausell et al., 2014) have primarily utilized conservation features.
However, these features are limited in distinguishing between LOF
variants of different classes in the same protein. Moreover, these
methods restrict their training sets to core proteins that have high
quality annotations, thereby reducing their utility on less well-studied
genes. To circumvent this issue, CADD (Kircher et al., 2014), a
method designed to predict the impact of all classes of genetic vari-
ation, was trained on simulated de novo and ancestral mutations.
DDIG-in further supplemented conservation-based features with in-
trinsic disorder predictions from the region affected by stop gain and
frameshifting variants (Folkman et al., 2015), whereas VEST-Indel
evaluates frameshifting indels via a random forest model, yet restricts
functional and structural features to stability, solvent accessibility and
the temperature factor (Douville et al., 2016). However, there are nu-
merous other structural and functional properties of proteins that
could potentially be impacted by LOF variants. The incorporation of
such information alongside features indicative of functional redun-
dancy of the protein into more complex predictive models is expected
to not only increase discriminative power but also suggest the specific
nature of functional impact in a principled manner.
To address these challenges, we study the evolutionary, struc-
tural and functional signatures of loss-of-function genetic variants.
We subsequently develop machine learning methods for the discrim-
ination of pathogenic from tolerated frameshifting and stop gain
variants and hypothesizing specific molecular alterations. Our re-
sults provide evidence that there is significant potential to analyze
the causal mechanisms for loss of function in these classes of vari-
ants and point out potential difficulties in developing computational
tools for automated prioritization of loss-of-function variants.
2 Materials and methods
2.1 Training data sets
Pathogenic (disease-causing) stop gain and frameshifting variants
were obtained from the July 2016 version of the Human Gene
Mutation Database (HGMD) (Stenson et al., 2014) and ClinVar
(Landrum et al., 2016). The set of putatively neutral variants was
composed of frameshifting and stop gain variants from ExAC which
were annotated to have passed all quality filters. To remove poten-
tial biases, we did not perform filtering based upon population fre-
quency and only retained canonical isoforms in subsequent analyses.
Table 1 summarizes all data sets.
2.2 Neurodevelopmental disorders dataset
We applied MutPred-LOF to a data set, curated from the published
literature, consisting of 970 de novo LOF variants identified through
whole-exome or whole-genome sequencing of individuals diagnosed
with six neurodevelopmental disorders, including autism spectrum
disorder (ASD), schizophrenia, intellectual disability, bipolar dis-
order, developmental delay and epileptic encephalopathy (de Ligt
et al., 2012; De Rubeis et al., 2014; EuroEPINOMICS-RES
Consortium, Epilepsy Phenome/Genome Project and Epi4K
Consortium, 2014; Epi4K Consortium and Epilepsy Phenome/
Genome Project, 2013; Fromer et al., 2014; Gilissen et al., 2014;
Girard et al., 2011; Guipponi et al., 2014; Gulsuner et al., 2013;
Hashimoto et al., 2016; Iossifov et al., 2012, 2014; Jiang et al.,
2013; Kong et al., 2012; McCarthy et al., 2014; Neale et al., 2012;
O’Roak et al., 2011, 2012a, b; Rauch et al., 2012; Sanders et al.,
2012; Turner et al., 2016; Xu et al., 2011; Xu et al., 2012; Yuen
et al., 2015, 2016; S.Jonathan et al., unpublished data, doi: https://
doi.org/10.1101/102327) and a control set of 172 de novo LOF mu-
tations from healthy siblings (Gulsuner et al., 2013; Iossifov et al.,
2012, 2014; O’Roak et al., 2011, 2012b; Rauch et al., 2012;
Sanders et al., 2012; Xu et al., 2011, 2012; S.Jonathan et al., unpub-
lished data, doi: https://doi.org/10.1101/102327).
2.3 Feature engineering
We created features for the description of each variant based upon
the properties of wildtype protein sequence, with features divided
into those representing portions of the protein sequence affected and
unaffected by the alteration. Amino acids occurring prior to the vari-
ant were considered to constitute the unaffected portion of the pro-
tein and are referred to in the text as the amino side (Fig. 1).
Residues that occur after the variant are likewise denoted as the
carboxyl side, either wildtype or mutant. The amino acid sequences
of the carboxyl side in mutant variants were not reconstructed from
the genomes for use in structural and functional property features;
incorporation of features based upon predicted mutant amino acid
sequence did not lead to improved performance and the exclusion of
these features greatly simplifies predictor development and its
Table 1. Number of variants (proteins) present in each data set
Disease Neutral Total
Frameshift 18 116 (1545) 90 135 (13 427) 108 251 (13 713)
Stop gain 14 318 (1681) 7960 (4990) 22 278 (6137)
Total 32 434 (1995) 98 095 (13 605)
The set of canonical sequences was derived from UniProt (Suzek et al.,
2007). The number of available stop-loss variants was too small to be
included in this work.
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application because the variants could be scored based on the wild-
type sequence only.
The feature space covers three classes: general sequence features,
evolutionary features and predicted structural and functional fea-
tures. Sequence-based features include the relative position of the
variant, the number of amino acids affected by the variant, binary
nonsense-mediated decay prediction based upon the 50 nucleotide
rule (variant is more than 50 nucleotides upstream of the final exon–
exon junction (Maquat, 2004), number of amino acids from the
variant to the final exon–exon junction, and a two-element binary
vector indicating the type of LOF variant (stop gain or frameshifting
insertion/deletion).
2.3.1 Evolutionary features
Evolutionary features involved general sequence conservation
indexes for amino/carboxyl sides of the protein as well as counts of
close homologs of the wildtype protein in the human and mouse
genomes. Conservation features for the wildtype sequence were ex-
tracted from two sources. First, we generated a position-specific
scoring matrix (PSSM) by running PSI-BLAST against the "nr" data-
base (Altschul et al., 1997). Second, we used AL2CO (Pei and
Grishin, 2001) to derive nine conservation indexes from the UCSC
Genome Browser 46-species alignment (Karolchik et al., 2014) for
each position in the sequence. Both normalized and unnormalized
versions of these scores were calculated for the whole alignment and
two sub-alignments (mammals only and primates only). To capture
the relative conservation of affected and unaffected regions of the
protein, we took the maximum conservation over the amino and
carboxyl sides of the protein as well as the difference between
these regions. This resulted in 342¼126 PSSM features and
3239¼162 AL2CO conservation features.
2.3.2 Structural and functional property features
The structural and functional features included both gene-based
and residue-based features. The gene-based features contained
2132-dimensional vectors of predicted Gene Ontology terms using
FANN-GO (Clark and Radivojac, 2011), where each variant in
the same protein received the same set of features. The predicted
features were used in order to mitigate biases that could arise due
to the fact that known disease genes are generally better studied
and contain more functional information than the remaining
genes.
We extended the gene-based feature space via the prediction of a
variety of residue-level structural and functional properties in the
wildtype protein that convert its amino acid sequence into a series of
real-valued vectors of the same length. We then used the method-
ology behind vector quantization kernels (Clark and Radivojac,
2014) to encode these property vectors into a fixed-length feature
representation. Vector quantization features address an important
challenge in encoding LOF variants as they facilitate encoding of
variable-length amino acid sequences into a fixed-length representa-
tion, beyond simple summary statistics. At the same time, they allow
for more effective use of external biological data to be incorporated
into method development via a series of prediction models previ-
ously constructed for given structural and functional properties.
Specifically, the vector quantization procedure involved a data
preprocessing step and a feature construction step. In the data pre-
processing step, we first defined the universe of human protein se-
quences S ¼ fs1; s2; s3; . . .g as the UniRef50 database (Suzek et al.,
2007), where each s 2 S is a string composed of amino acids from
A ¼ fA;C; . . . ;Yg. For each s 2 S, we mapped the protein sequence
into a real-valued property vector p ¼ ðp1;p2; . . . ;plÞ, where l is
length of the string s, using any particular feature mapping described
in Table 2. For example, predicting the helical propensity for a given
sequence s results in one such vector p of numbers between 0 and 1.
Next, we decomposed the property vector into n-dimensional over-
lapping subvectors p½1;n; p½2;nþ1; . . . ; p½lnþ1;l, where p½1;n represents
the first n elements of p. The process was repeated for each protein
sequence to create a large database of n-dimensional fragments for a
particular property. This database of fragments was then clustered
using the K-means algorithm into m groups to generate a partition
to m regions R ¼ fR1;R2; . . . ;Rmg, represented by centroids
C ¼ fc1; c2; . . . ; cmg. Each centroid is associated with a Voronoi re-
gion, Ri, such that
Ri ¼ fx : dðx; ciÞ  dðx; cjÞ; i 6¼ jg; (1)
where d(x, c) is the Euclidean distance between fragment x and cen-
troid c. One such clustering was created for each property and a set of
m centroids per property was stored. In the feature construction step,
a particular property was first predicted for the wildtype sequence and
a set of length-n segments within the amino and carboxyl regions rela-
tive to the variant position were extracted. A set of features was then
created for each side by counting the segments closest to each of the
UniRef50-derived centroids; i.e., the count at position i corresponds
to the number of fragments closest to the i-th centroid. Two vectors of
counts, one for the amino and one for the carboxyl side, were created
for each property. Based on previous work, and with minimal experi-
mentation, we chose n¼16 and m¼16 (Clark and Radivojac, 2014).
This vector quantization framework was utilized on both the carboxyl
and amino side sequence fragments for the 57 structural and func-
tional features to derive a total of 57162¼1824 features.
Overall, the data set contained 4270 features.
2.4 Predictor development
An ensemble of one hundred bagged two-layer feed-forward neural
networks was trained for all loss-of-function variants collectively
utilizing the Matlab Neural Network Toolbox. The number of hid-
den units in each network was fixed at 10. To eliminate features
very likely to be uninformative, we applied a two-sample t-test with
a high P-value threshold of 0.5. Furthermore, we applied principal
component analysis with 99% retained variance on z-score normal-
ized data to reduce dimensionality and eliminate (near-)colinear fea-
tures. The resilient propagation method was used for training with
25% of the training data used as validation (Riedmiller and Braun,
1993). All parameters were set prior to training and were not varied.
Finally, all models were trained on balanced training sets, where the
majority class was subsampled.
2.5 Predictor evaluation
Performance of MutPred-LOF is represented by the area under the
ROC curve (AUC) derived from scores generated in 10-fold per-
Wildtype
Mutant
variant
Carboxyl side mutant
Amino side wild Carboxyl side wild
Fig. 1. Illustration of the impacted portions of the protein for loss-of-function
variants. The impacted region can be shorter or longer for the mutant protein
(if translated); its length is zero for the stop gain variants
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protein cross-validation. All pre-processing steps (normalization,
dimensionality reduction) were carried out on the training partition
only and applied on the test partition. To ensure that the model did
not suffer from over-reliance on protein-based features, we performed
per-protein cross-validation such that for each fold all variants in a
protein were either entirely in the training or test set. We illustrate
the influence of gene-based features on estimated performance
of MutPred-LOF using three types of cross-validation protocols:
(1) per-variant, (2) per-protein and (3) per-cluster. Per-variant cross-
validation considers all variants as independent data points and parti-
tions variants into ten-folds without consideration of the proteins
from which the set is derived. In contrast, per-protein cross-validation
ensures in each fold that all variants from the same protein are either
in the training or in the test partition. This evaluation protocol ensures
better performance estimation when the model is presented with a
variant in protein that was not in the training set or that contained
only one type of variant (e.g., disease-associated). In per-cluster cross-
validation, variants within proteins with at least 50% sequence iden-
tity were included in either training or test sets, and can be used to
estimate performance when the model is presented with a protein for
which no protein within 50% sequence identity was available in the
training set. We also used this evaluation protocol to assess the over-
fitting potential of the per-protein performance assessment.
Next, we compared the performance of MutPred-LOF against
three currently available methods, each of which was evaluated using
a set of frameshifting and stop gain variants from the MutPred-LOF
training set. Deleterious variants from HGMD professional version
2016 that were not present in HGMD 2015 were extracted to repre-
sent a set of deleterious variants that are unlikely to be included in the
training data of these methods (2,409 variants from 745 genes). The
neutral test set consisted of variants from the ExAC training data
(43,534 variants from 11,098 genes). The test set was filtered to re-
move the training data from DDIG-in and Vest-Indel; this procedure,
however, could not be replicated for the CADD training data.
Further, we created a for-comparison-only version of MutPred-LOF,
MutPred-LOF0, with these test set variants removed from the training
data, to ensure that for every model in this comparison the test vari-
ants were not included in the training set.
2.6 Assessing significance of functional alterations
To identify loss-of-function variants with significant functional im-
pact, we defined a P-value for each feature listed in Table 2 to assign
significance and rank prospective mechanisms. In the development
of MutPred (Li et al., 2009), a method that predicts the impact of
single amino acid substitutions, we constructed empirical P-values
as follows. The null distribution was first defined using the scores of
functional disruption for all variants present in the set of putatively
neutral substitutions. Then, given a score of functional disruption
for a new variant, the P-value is determined as the fraction of neutral
substitutions with disruption scores at least as high as the observed
value. This method relies on two strong assumptions: (1) that each
functional mechanism is equally disrupted in the set of neutral sub-
stitutions, and (2) that each functional mechanism is equally likely.
In this work, we rank functional disruption scores by modifying
MutPred’s approach so as to mitigate the latter assumption.
Specifically, we rank the molecular mechanisms by adjusting the
P-values as
P0 ¼ ð1 aÞ  P; (2)
where P is the P-value assigned in a way identical to MutPred’s ap-
proach and a is the frequency of a particular functional mechanism.
We refer to this quantity as prior-corrected P-value. The rationale
for this adjustment comes from the definition of the false discovery
rate (FDR); i.e.,
FDR ¼
ð1 aÞ  FPR
a  TPRþ ð1 aÞ  FPR
; (3)
where TPR is the true positive rate and FPR is the false positive rate.
Here, we use the P-value as an approximation of the false positive
rate and ignore the denominator. Ideally, molecular alterations
would be prioritized based on the posterior probability that a par-
ticular mechanism (e.g., DNA binding, or protein binding) is dis-
rupted. However, this step either requires a data set of disrupted and
non-disrupted mechanisms that can be used to estimate true positive
and false positive rates or further assumptions on how to probabilis-
tically reason on the disruption of structural/functional propensity
for entire protein regions based on such propensities on a single-
residue basis.
The scoring function that was used to determine the empirical
null distribution and assign P-values was the number of residues
with high structural and functional propensities. The thresholds for
these high propensity scores were determined separately for each in-
dividual model described in Table 2 during the training phase (low
false positive rates; here, 10%). On the other hand, the prior
Table 2. Predicted structural and functional features
Property category Predicted features
Structure and
dynamics
Three classes*—Helix, strand, loop; Intrinsic disorder (Peng et al., 2006); B-factor (Radivojac et al., 2004); Relative solvent
accessibility*; Coiled-coil region*
Signal peptide and
transmembrane
regions*
Seven classes—N- and C-termini of signal peptide, signal helix, signal peptide cleavage site, transmembrane segment, cyto-
plasmic and non-cytoplasmic loops
Enzyme activity* Catalytic residues
Regulation* Allosteric residues
Macromolecular
binding
DNA*; RNA*; Protein-protein interaction (PPI)*; PPI hotspots*; Molecular Recognition Features (MoRFs)*; Calmodulin-
binding (Radivojac et al., 2006)
Metal-binding* Cd; Ca; Co; Cu; Fe; Mg; Mn; Ni; K; Na; Zn
Post-translational
modification
(PTM) (Pejaver
et al., 2014)
Acetylation, ADP-ribosylation, Amidation, Carboxylation, Disulfide linkage, Farnesylation, Geranylgeranylation,
Glycosylation (C-linked, N-linked and O-linked), GPI anchor amidation, Hydroxylation, Methylation, Myristoylation,
N-terminal acetylation, Palmitoylation, Phosphorylation, Proteolytic cleavage, Pyrrolidone carboxylic acid, Sulfation,
SUMOylation, Ubiquitylation
Motifs From PROSITE (Sigrist et al., 2013) and ELM (Dinkel et al., 2014)
*Indicates in-house predictors.
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probabilities that a particular residue has a specific property were
estimated using the AlphaMax algorithm (Jain et al., 2016).
2.7 MutPred-LOF output
For every mutation input into MutPred-LOF, the model returns a
score between zero and one, where variants with higher scores are
more likely to be pathogenic. In addition, MutPred-LOF returns up
to five structural and functional mechanisms that are impacted in
the affected region of the protein, and have significant prior-
corrected P-values (less than 0.05). For the purposes of classifica-
tion, we provide three score thresholds to aid users in discriminating
between pathogenic and neutral variation, at different levels of false
positive rate (FPR): 0.40 (10% FPR), 0.50 (5% FPR, recom-
mended), 0.70 (1% FPR).
3 Results
3.1 Evolutionary conservation of loss-of-function
variants
Conservation has consistently been shown to be a key signature of
pathogenic variants (Ng and Henikoff, 2003). Unsurprisingly, these
features were also shown to be informative across all variant types
in our data. To highlight the differences in conservation between
pathogenic and neutral loss-of-function variants, Figure 2 shows a
representative plot created from one of the conservation metrics.
The plots show the approximate probability density function of
average unnormalized unweighted entropy in the vertebrate align-
ment for amino and carboxyl sides of the wildtype sequences. While
the affected region in disease-associated variants is more conserved
than that of the neutral variants, the similarity between distributions
of conservation between amino and carboxyl sides indicates that the
conservation of the protein as a whole plays a dominant role.
Therefore, for such a feature to be sufficiently effective in discrimi-
nating between pathogenic and neutral variants, the training set
would need to contain both types of variants for most proteins,
which is currently not the case.
An alternative metric to analyze sequence conservation between
variation is the number of closely related proteins. Functional redun-
dancy in the genome, as measured by the number of closely related
paralogs has been shown to be associated with neutral loss-of-
function variants (MacArthur et al., 2012) and genes with homologs
that have 90% sequence identity are three times less likely to harbor
disease variants (Hsiao and Vitkup, 2008). To test if our data were
consistent with this trend, we counted sequences with high sequence
identity in human and mouse proteomes. The average number of
homologs in overlapping sequence identity regions for each class of
loss-of-function variation are shown in Figure 3. In the human-
human comparison, proteins containing pathogenic variants tend to
have fewer similar proteins across all levels of sequence identity than
proteins containing neutral variants. Broadly speaking, this suggests
increased robustness of the system through functional redundancy;
i.e., it allows very similar proteins to compensate for one another.
On the other hand, human-mouse protein comparisons show the op-
posite trend. Proteins with disease-associated variants tend to have
more homologs in the mouse genome than proteins with neutral
variants. Although trends remain consistent, the magnitude between
the average homolog count differs between the types of variant. This
discrepancy may partially be due to biases in the data sets but may
also reflect evolutionary constraints underlying sequences suscep-
tible to each variant type.
Generally, our results agree with previous observations suggest-
ing the importance of evolutionary conservation for identifying
disease-associated variants. However, we also find that disease vari-
ants are often located in more evolutionarily conserved proteins
compared to the neutral variants suggesting limitations in using such
information as a sole discriminator of pathogenicity of variants. The
homology profiles from Figure 3 also support previous observations
that proteins harboring disease variants tend to have fewer homo-
logs in the human genome but more homologs in the genomes of
model organisms compared to other proteins (Hsiao and Vitkup,
2008; Mushegian et al., 1997).
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Fig. 2. Approximate probability density functions of an average conservation
measure of the wildtype protein (A) at the amino side of the variant and (B) at
the carboxyl side of the variant for pathogenic (blue) and neutral (orange)
variants. To ensure clarity, we omit proteins that contain both pathogenic and
neutral variants from this figure. Proteins harboring disease variants are gen-
erally more conserved at both sides of the variant
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Fig. 3. Homology profiles for the types of loss-of-function variants. Each plot
shows the average number of sequences affected by pathogenic and puta-
tively neutral variants, within a particular range of global sequence identity
against human and mouse genomes
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3.2 Prediction evaluation
Classifier performance is reported as the area under the ROC curve
(AUC) and shown in Figure 4. In panel A, we show the AUC of al-
ternative models based upon per-variant, per-protein and per-cluster
cross-validation. The per-variant version of MutPred-LOF outper-
forms per-gene and per-cluster methods as a result of the model ex-
hibiting over reliance on gene-specific features. The per-gene and
per-cluster versions show comparable performance, and thus further
analyses are carried out using the per-gene evaluation. Additionally,
we assessed the performance of an alternative model utilizing per-
cluster cross-validation with 25% sequence similarity and found
similar performance to the 50% sequence identity threshold (data
not shown). Figure 4B shows the performance of MutPred-LOF on
the two types of loss-of-function variants separately. We see that the
performance of stop gain variants is significantly lower than frame-
shifting variants, which have higher collective performance. We
observed that models developed specifically for each variant type
show similar, but worse collective performance than a single unified
model (data not shown). Finally, we compared the performance of
MutPred-LOF against three currently available tools in Figure 4C.
We define a set of proteins which contain both neutral and patho-
genic variants as bi-class proteins, and similarly derive a set of vari-
ants contained in those proteins as the bi-class subset. We observe
that MutPred-LOF and CADD show reduced performance on the
bi-class subset compared to the full set of variants whereas the other
methods show significantly degraded performance on subset of vari-
ants in bi-class proteins. This suggests that MutPred-LOF is less de-
pendent on the global protein-specific attributes that may simply be
reflective of the signatures of disease genes. Although we have car-
ried out as stringent a comparison as possible, community-wide as-
sessments such as the Critical Assessment of Genome Interpretation
(CAGI) will be able to further establish performance of all available
methods on a common set of variants in the future.
3.3 Performance of feature sets
We investigated the predictive capacity of each individual feature
subset on the performance of MutPred-LOF for frameshifting and
stop-gain variants. To accomplish this, we generated a neural net-
work model with the same parameters as the full MutPred-LOF but
with a reduced feature set, shown in Table 3. Values in Table 3 cor-
respond to features discussed in Section 2.3. Here we also observe
metal binding and predicted GO terms show performance on par
with conservation-based features. Any individual feature subset,
particularly vector quantized functional features, are not sufficient
to discriminate between pathogenic and neutral variants. However,
if any feature set is removed from the training data then the AUC of
the full model drops by several points (data not shown).
3.4 Phenotype-specific impact on structural and
functional features
We identified structural and functional features that exhibit differ-
ences between pathogenic variants and the neutral background, re-
flected in a P-value with respect to a given feature. To ascertain the
discriminative capacity of these P-values for individual proteins, we
identified and analyzed several proteins that can represent typical
use cases. For these examples, we selected proteins which contain
both pathogenic and putatively neutral variants, to highlight func-
tional differences underlying proteins with both disease-causing and
neutral loss-of-function variants.
3.4.1 pcdh19
Several mutations in Protocadherin-19 (PCDH19) are included in
the training data, including two putatively neutral variants from
ExAC and dozens of pathogenic variants from HGMD, all of which
have been predicted accurately in cross-validation. Mutations in
PCDH19 have been identified as causative for early infantile epilep-
tic encephalopathy 9, a disease shown to exhibit variable expressiv-
ity (Depienne and LeGuern, 2012). In this case, the two neutral
variants occur towards the carboxyl-terminus representing an ideal
use case of MutPred-LOF on a bi-class protein. In particular, the
neutral variants occur in the final 50 amino acids of the protein and
do not directly impact the primary Protocadherin-19 domain in the
protein. Additionally, MutPred-LOF uncovers several molecular
mechanisms significantly disrupted by these pathogenic variants
including calcium binding, phosphorylation and palmitoylation,
that are not identified in the neutral variants.
3.4.2 sim1
The Single-minded homolog 1 (SIM1) protein similarly contains
both a pathogenic variant and several putatively neutral variants.
Previously discovered loss-of-function mutations in SIM1 result in
haploinsuffciency and subsequent hypodevelopment of paraven-
tricular nuclei in the hypothalamus, and have been associated with
severe early-onset obesity and Prader-Willi-like syndrome features
(Bonnefond et al., 2013). The pathogenic variant abolishes the
majority of a PAS domain, including a ubiquitination site
(P0 ¼ 0:0265), whereas the neutral variants impact a portion of the
C-terminal single-minded domain. These putatively neutral variants
may still be associated with obesity if derived from obese ExAC par-
ticipants, depending upon the inclusion criteria for particular stud-
ies. The neutral variants impact the C-terminal Single Minded
domain, which has proposed relationship to transcriptional regula-
tion of SIM1 and therefore may still have some clinical relevance
(Ramachandrappa et al., 2013).
3.5 Performance on de novo variants in
neurodevelopmental disorders
We applied MutPred-LOF to de novo loss-of-function variants that
have been observed in whole exome and whole genome sequencing
of families affected by neurodevlopmental disorder (de novo variant
set and MutPred-LOF scores are available on the website). In this
setting, the case variants may include a large fraction of non-
pathogenic variants and so the performance of MutPred-LOF on this
set cannot be accurately assessed in a binary classification frame-
work (Jain et al., 2017). To this end, we utilized a Fisher’s exact test
to determine if there is a significantly higher proportion of LOF vari-
ants predicted to be pathogenic in the case samples than in the con-
trol samples, shown in Figure 4D. For the threshold associated with
5% false positive rate, we find that 56% (547/970) of the case LOF
variants are scored with high confidence to be pathogenic compared
to only 46% (79/172) of the control variants (P¼0.0071). For the
threshold associated with 10% false positive rate, we find that 86%
(839/970) of the case variants are scored with high confidence to be
pathogenic compared to only 80% (137/172) of the control variants
(P¼0.0152). The excess of LOF variants has been previously
observed in the patients with autism compared to their healthy sib-
lings (Iossifov et al., 2012). The fact that we observe a significantly
higher fraction of predicted pathogenic LOFs in the patients com-
pared to controls suggests that LOF variants may have an important
role in neurodevelopmental diseases.
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4 Discussion
Understanding the repertoire of molecular alterations consequent to
genetic variation is essential to advancing personalized medicine
(Rost et al., 2016). Severe alterations in mRNA transcripts resulting
from stop variants and frameshifting indels are particularly chal-
lenging because of their potentially major impact on the sequence of
translated proteins as well as on their structure and function. To ad-
dress these challenges, we assembled a large data set of human gen-
etic variants and analyzed specific types of molecular alterations
that could potentially be causative of underlying diseases. Using in-
sights from this analysis, we developed a computational model
MutPred-LOF, an extension to our variant predictor MutPred (Li
et al., 2009), to discriminate between pathogenic and tolerated puta-
tively loss-of-function variants. MutPred-LOF exploits detailed evo-
lutionary and functional information to classify LOF variation
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Fig. 4. Receiver operating characteristic (ROC) curves and Areas Under the ROC Curves (AUC). (A) Cross-validation performance of MutPred-LOF with per-variant,
per-protein, and per-cluster cross-validation; (B) Cross-validation performance of MutPred-LOF for frameshifting and stop gain variants separately; (C) The per-
formance for other methods based upon the testing set. Black curves represent the performance of MutPred-LOF0. The dotted line represents performance of
each model on the subset of variants from bi-class proteins; (D) Proportion of high-scoring de novo variants implicated in neurodevelopmental disorders in the
case and control datasets based upon 5 and 10% false positive rate thresholds. The P-value derived from Fishers exact test is shown above
Table 3. Per-feature evaluation: top ten performing feature sets
Feature set Full model
Predicted GO Terms 0.729
Maximum conservation 0.707
Metal binding 0.660
Structure and dynamics 0.652
Enzyme activity 0.645
Regulation 0.641
Macromolecular binding 0.633
Homology counts 0.614
Post-translational modification 0.611
Signal peptide and transmembrane 0.610
For each set of features we train ensembles of neural networks with the
same parameters in all models. The performance (AUC) of a model trained on
a feature set is used to estimate the performance of each feature separately.
When loss-of-function is loss of function i395
from different and disparate contexts including severely pathogenic
variation, pathogenic recessive variants in a heterozygous state, vari-
ants tolerated due to gene redundancy and sequencing errors
(MacArthur et al., 2012). In addition to providing a classification
score for pathogenic vs. tolerated variants, MutPred-LOF provides
hypotheses regarding affected molecular events that might be re-
sponsible for pathogenicity of the variant.
4.1 Evolutionary conservation vs. structure and function
In the course of our study, we were particularly interested in under-
standing the influence of evolutionary conservation as well as
structural and functional impact of the variant. Because pathogenic
loss-of-function variants cover a relatively small subset of human
genes, we found that a straightforward analysis may be misleading
and is likely to recover signatures of known disease genes (Dalkilic
et al., 2008), instead of properly accounting for the combined influ-
ence of the gene and variant features. To effectively include protein
structure and function, we incorporated over 50 computational mod-
els that output positional propensities for several major types of struc-
tural and functional features. These models were integrated via a
vector quantization-like approach into a rich feature representation.
The estimated accuracy of MutPred-LOF suggests that the inclusion of
additional features was beneficial in the modeling process.
4.2 Positive-unlabeled learning framework
Technically, our classification setting falls under the category of
positive-unlabeled learning (Denis et al., 2005), with a further cav-
eat that a fraction of positive data might be incorrectly labeled.
Recent advances in machine learning suggest that, under mild as-
sumptions, the traditional supervised models trained on positive vs.
negative examples provide the same ranking as the (non-traditional)
models trained on positive vs. unlabeled examples (Blanchard et al.,
2010; Elkan and Noto, 2008; Menon et al., 2015). Moreover, if the
class prior probability is known or can be estimated, one may fur-
ther exploit the following: (1) there exists a monotonic relationship
between the traditional and non-traditional posterior class distribu-
tions (Jain et al., 2016) and (2) the performance accuracy in the
non-traditional setting can be corrected to reflect the performance
accuracy in the traditional setting (Jain et al., 2017). Given these
theoretical results, we decided to use the entire ExAC database as a
set of ‘negative’ examples in our training procedure, with the reason-
ing that filtering out a subset of variants (e.g., rare variants) is more
likely to be harmful by biasing the sample than class label noise.
4.3 A note on terminology
Loss-of-function variants are defined here as frameshifting and stop
gain variants. The term can be considered a misnomer, due to the
potential for the interpretation that ‘loss of function’ implies axio-
matic loss of functional activity. Instead, we use the term to refer to
a class of variants that are likely to result in profound impact on the
protein, similar to the term ‘protein disrupting variant’. Loss-of-
function variants, although frequently causing disease, are likely
present in every human genome. Misinterpretation of the impact of
a variant that would appear to result in loss of molecular function
can lead to attributing phenotype to the wrong root molecular
cause.
By using this terminology, we sought to emphasize that the ex-
tent of impact on function lies on a spectrum from the absolute abo-
lition of function, to reduction of functional capacity and, finally,
no phenotypic consequence. Adding an additional layer of complex-
ity, we allowed for the fact that functional impact may or may not
result in pathogenicity. One of the objectives behind the develop-
ment of MutPred-LOF is to clarify the relationship between molecu-
lar function and pathogenicity by allowing potential users to make a
more informed assessment based upon both pathogenicity predic-
tion and impacted molecular function. To this end, we provided two
separate scoring mechanisms, and embrace the complexity underly-
ing loss-of-function variation.
4.4 Limitations
While MutPred-LOF showed good performance, shortcomings in
the training data and method development may be a limitation.
Context-based genetic information such as zygosity or haplotype are
typically not known since publicly available databases are com-
monly stripped of this information to maintain participant anonym-
ity. The mutational context including rescuing frameshifting
mutations and relevant variation within the gene or pathway is im-
portant to consider in causative variant discovery. Population bias
and undiscovered pathogenic variation in the neutral data set may
also have unintended impact on the final model. Finally, in the
method development step, we do not encode properties of the mu-
tant protein sequence, thereby excluding outcomes such as splice
site disruptions that may not damage the entire protein sequence
downstream of the variant. Reduced performance on bi-class vari-
ants highlights difficulties in discrimination between variants in bi-
class genes will continue to be of particular difficulty and should be
further emphasized.
4.5 Final thoughts
We believe that our analysis provides new insights into the under-
standing of loss-of-function variants, especially the interplay be-
tween protein-specific and variant-specific features. MutPred-LOF
encodes both types of features and shows the ability to differentiate
between disease-causing and tolerated loss-of-function mutations,
especially those occurring in the bi-class proteins. As such, MutPred-
LOF allows for the specialized interpretation of one of the most
impactful forms of genetic variation to facilitate variant and genome
interpretation.
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